Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

May 31, 2008

Conditions

Carcinoma, Renal Cell Metastasis

Interventions

DRUG

SU011248 (sunitinib)

37.5 mg/day, oral, continuous daily dosing

Trial Locations (10)

Pfizer Investigational Site, Berlin

Pfizer Investigational Site, Thessaloniki

Pfizer Investigational Site, München

Pfizer Investigational Site, Las Vegas

Pfizer Investigational Site, Stanford

Pfizer Investigational Site, Villejuif

Pfizer Investigational Site, Nijmegen

Pfizer Investigational Site, Lund

Pfizer Investigational Site, Stockholm

Pfizer Investigational Site, Sankt Gallen